Several key members of the House of Representatives are urging the US Food & Drug Administration to back up its public statements about “flexibility” in considering ALS therapies with some concrete actions.
House Energy & Commerce/Health Subcommittee Chair Anna Eshoo (D-CA) organized the bipartisan letter, and ranking member Brett Guthrie (R-KY)...







